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Abstract
Background: Soft tissue sarcoma (STS) is an anatomically and histologically heterogeneous neoplasia that shares a putative
mesenchymal cell origin. The treatment with common chemotherapeutics is still unsatisfying because of association with
poor response rates. Although evidence is accumulating for potent oncolytic activity of host defense peptides (HDPs), their
potential therapeutic use is often limited by poor bioavailability and inactivation in serum. Therefore, we tested the designer
host defense-like lytic D,L-amino acid peptide [D]-K3H3L9 on two STS cell lines in vitro and also in an athymic and syngeneic
mouse model. In recent studies the peptide could show selectivity against prostate carcinoma cells and also an active state
in serum.
Methods: In vitro the human synovial sarcoma cell line SW982, the murine fibrosarcoma cell line BFS-1 and primary human
fibroblasts as a control were exposed to [D]-K3H3L9, a 15mer D,L-amino acid designer HDP. Cell vitality in physiological and
acidic conditions (MTT-assay), cell growth (BrdU) and DNA-fragmentation (TUNEL) were investigated. Membrane damage at
different time points could be analyzed with LDH assay. An antibody against the tested peptide and recordings using
scanning electron microscopy could give an inside in the mode of action. In vivo [D]-K3H3L9 was administered intratumorally
in an athymic and syngeneic (immunocompetent) mouse model with SW982 and BFS-1 cells, respectively. After three weeks
tumor sections were histologically analyzed.
Results: The peptide exerts rapid and high significant cytotoxicity and antiproliferating activity against the malignant cell
lines, apparently via a membrane disrupting mode of action. The local intratumoral administration of [D]-K3H3L9 in the
athymic and syngeneic mice models significantly inhibited tumor progression. The histological analyses of the tumor
sections revealed a significant antiproliferative, antiangiogenic activity of the treatment group.
Conclusion: These findings demonstrate the in vitro and in vivo oncolytic activity of [D]-K3H3L9 in athymic and syngeneic
mouse models.
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Introduction
Soft tissue sarcomas (STS) are a group of histologically and
genetically diverse neoplasms that account for approximately 1%
of all adult malignancies [1]. STS are of putative mesenchymal
derivation and can involve connective tissue structures as well as
viscera and integument anywhere in the human body [1]. Overall
survival is approximately 50% at 5 years [2] and up to 60% of
high grade STS develop distant metastases [3]; these data support
the use of an aggressive approach for the treatment STS. Effective
treatment usually requires surgical ablation in combination with
radiotherapy and/or chemotherapy as the clinical gold standard
and could improve the local control rates [4]. In spite of this
promising therapeutic treatment local relapse still occurs in up to
22% of the patients [5,6]. Unfortunately, late diagnosis often
results in distant metastases primarily via the hematogenous route
and particularly to the lungs (70–80%) [7].
Chemotherapeutic drugs damage malignant cells by a variety of
mechanisms (e.g., DNA cleavage/alkylation and topoisomerase II
inhibition) that are eventually translated into apoptotic signals.
Unfortunately, STS does not respond well to single or multiple
drug regimens [8]. In addition, chemical oncolytic agents are
nonspecific and, consequently, damage healthy tissues as well.
This has stimulated the search for new oncolytic agents with new
modes of action and with a potential to overcome the inherent
resistance [9,10].
Host defense peptides (HDPs) have aroused interest as potential
oncolytic agents that overcome the limits of current drugs [10,11].
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18321As part of the innate immune system, HDPs are expressed in
nearly every kind of organism, from plants over amphibians to
mammals [10].
Initially classified as exclusively antimicrobial active substances,
HDPs have demonstrated significant cytotoxic effects against a
wide range of malignant cells including e.g. melanoma, breast- and
lung cancer [10,12,13]. The oncolytic effect of HDPs depends on
their amphipathic, cationic structure [14]. The positive charge of
the peptides is proposed to initiate electrostatic interaction with the
negatively charged membrane of tumor cells which could lead to
permeation of the peptide into the membrane and a subsequent
complete membrane disruption [10,14,15,16,17].
Despite the potent oncolytic activity of these peptides in vitro,
studiesinvivoareverylimited,mainlybecauseoftheirinactivationin
serum, partially because of their binding to serum components and
their enzymatic degradation. This has led to the development of
synthetic D-amino acid analogues. D-amino acid peptides could
show potent oncolytic activity and high selectivity in prostate
carcinoma and preserved their activity also in xenograft models in
vivo [18,19]. The differences between naturally occurring lytic L-
compared to artificially synthesized D-amino acid peptides is their
modified structure. While in solution both peptides show unordered
structure characteristics, in and on membranes they have different
behaviors. L-amino acids often assume a-helical structures. D-
amino acids instead can bind better to negatively charged
membranes of tumors than to zwitterionic membranes of normal
mammalian cells [19]. Another important point is the pH
dependence of HDPs. Frequently tumor tissue possesses an acidic
extracellular milieu because of the disordered metabolic and
nutritional environment [20,21,22]. Much current research is
focused on designing HDPs which are only active in acidic
environment, as this may be promising feature in oncolytic
treatment. The host defense-like lytic peptide [D]-K3H3L9 used in
this study is composed of the D- and L-amino acids lysine, histidine
and leucin. Histidine (pKa, ,6.1) is protonated below pH 7
[23,24]. The acidic environment created by solid tumors activates
the HDP by making it cationic. Therefore selectivity against
malignant tissue is achieved. In previous studies the [D]-K3H3L9
peptide has already shown an oncolytic activity against prostate
carcinoma in cell culture and also in an in vivo xenograft model [23].
The aim of this study was to assess the oncolytic activity of the
D-amino acid peptide [D]-K3H3L9 in an athymic and immuno-
competent model and to analyze the potential of this peptide as a
therapeutic option against STS [25].
Materials and Methods
Ethics statement
Human ethics. The participants gave their written informed
consent, and the study was reviewed and approved by the ethical
committee of the BG University Hospital Bergmannsheil, Ruhr-
University Bochum, Germany with the permit number 2353.
Animalethics. Thetreatedanimalswere congenitally athymic
nude mice (Foxn1nu/nu) (Harlan Winkelmann GmbH, Borchen,
Germany) and immunocompetent C57BL/6 mice, 5–6 weeks old,
weighingabout20–25 g.Theywerehousedinventilated,pathogen-
free racks under a 12 h light-dark photoperiodicity with controlled
humidity and temperature (2362uC). Sterility was maintained
during all surgical procedures.
The Animal Care and Use Committee at the district government
of North Rhine Westphalia in Arnsberg, Germany approved all
animal experiments with the permit numbers 9.93.2.10.32.07.026
and 8.87-50.10.37.09.235. It was conducted in compliance with the
Guide for the Care and Use of Laboratory Animals’ from the
German Animal Welfare Act, which conforms to the provisions of
the Declaration of Helsinki in 1995.
Cell culture
The SW982 human synovial sarcoma cell line (Cell Line Service
(CLS), Eppelheim, Germany), last authenticated via nonaplex PCR
in July, 2008) was grown in DMEM supplemented with 10% FCS
(Thermo Fisher Scientific Inc., Waltham, MA, USA) and 1%
penicillin/streptomycin (PAA laboratories, Pasching, Austria). The
murine fibrosarcoma cell line BFS-1wt (generously provided by
Prof. T. Hehlgans, Department of Immunology, Regensburg,
Germany) were maintained in RPMI 1640 supplemented with 10%
FCS and antibiotics. The primary human fibroblasts were isolated
from patients’ tissue at the BG University Hospital Bergmannsheil.
Thestudy was approvedby the localethicscommittee, and all ofthe
patients gave written informed consent. For preparation of the
freshly received human skin dermis was separated from epidermis.
Primary human fibroblasts were obtained as previously described
[26].Allcellswereculturedat37uCinahumifiedatmosphereof5%
CO2. Before starting the experiments, cells were grown to
confluence, changing medium twice a week.
Peptide synthesis and purification
The host defense-like lytic peptide [D]-K3H3L9 was synthesized
by a solid-phase method and purified by RP-HPLC (NeoMPS
S.A., Strasbourg, France). The sequence of the peptide was a
generous gift of Prof. Yechiel Shai, Department of Biological
Chemistry, The Weizmann Institute of Science, Rehovot, Israel.
[D]-K3H3L9 is a short 15-mer D,L-amino acid peptide analogue
(LHLLHKLLKHLLKLL-NH2, underlined letters are D-amino
acids).
Cell vitality
The metabolic activity was measured via MTT assay according
to the standard protocol. Short: Cells were seeded in 96-well
microtiter plates (Corning Inc., New York, NY, USA) in a
concentration of 1610
4 cells per well. The following day, cells
were incubated in FCS-free media with different concentrations of
[D]-K3H3L9 (0–100 mM) for 24 hours. Thereafter the cells were
incubated in fresh media containing Thiazolyl Blue Tetrazolium
Bromid (MTT) solution for another 4 hours. Vital cells integrated
the dye as a sign of active metabolism. Dimethyl sulfoxide
(DMSO) (Carl Roth GmbH, Karlsruhe, Germany) and glycine
buffer (containing 0.1M glycine, 0.1M NaCl, pH 10.5, adjusted
with NaOH) were added to the wells. The amount of integrated
dye represented the level of metabolism and was quantified at
562 nm by an Elx808 Ultra Microplate Reader (Bio-Tek
Instruments GmbH, Bad Friedrichshall, Germany). The LD50
for each cell type was obtained from the dose-dependent cell
viability curves. The test was carried out at physiological and
acidic conditions (pH 7.3 and pH 6.0).
Cell proliferation
The cell proliferation was measured via BrdU cell proliferation
enzyme-linked immunosorbent assay (ELISA) kit (Roche Diag-
nostics GmbH, Mannheim, Germany) according to the manufac-
turer’s instructions. Briefly, cells were seeded at 3610
4 cells/well in
96-well plates, grown for 24 hours and then incubated with fresh
FCS-free medium containing the host defense-like lytic peptide
[D]-K3H3L9 (0–100 mM) for 24 hours.
BrdU labeling solution was added and incubated for another
22 hours. Proliferating cells integrated BrdU, a pyrimidine
analogue, into their DNA. The level of proliferation was quantified
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(BertholdDetectionSystems,Pforzheim,Germany).LD50valuesfor
each cell type were evaluated. Cell proliferation was determined in
triplicate. The results are expressed as a percentage of the cell
viability in comparison to the negative control.
DNA fragmentation
Cells undergoing DNA-cleavage were detected via a terminal
deoxynucleotidyl transferase (TdT)-mediated 29-deoxyuridine 59-
triphosphate (dUTP) nick-end labeling (TUNEL) assay. Cells were
seeded on chamber slides (Nalge Nunc International, Naperville,
IL, USA) at 35,000 cells per chamber, grown for 24 hours and
then incubated with [D]-K3H3L9 (0 mM–62.5 mM) for 24 h. After
fixation with 4% formaldehyde solution (Carl Roth GmbH,
Karlsruhe, Germany) cells were treated with TdT (Roche
Diagnostics GmbH, Mannheim, Germany). Slides treated with
DNase I (Qiagen Incorporated, Valencia, CA, USA) served as
positive controls. Slides treated without TdT served as negative
controls. TdT catalyzed the addition of fluorescent dUTP
(Invitrogen, Eugene,OR, USA) to DNA fragments caused by
DNA-cleavage. Cells labeled with dUTP were detected and
evaluated microscopically via a Zeiss Axioskop 2 Plus microscope
(Carl Zeiss Jena GmbH, Jena, Germany). All experiments were
performed in triplicate. Pictures were taken using the software
Zeiss Axio Vision 3.1. (Carl Zeiss Jena GmbH, Jena, Germany).
Membrane integrity
The membrane integrity of the cells after incubation with [D]-
K3H3L9 was measured by LDH release. The used CytoTox 96H
Non-Radioactive Cytotoxicity assay (Promega, Madison, WI,
USA) was done parallel to the MTT assay at different time points
(2 min, 15 min, 30 min, 2 h, 4 h, 24 h) and after incubation with
the peptide at 1, 2 and 4 multiples of the LD50 values. The kinetic
rate for cytotoxicity was monitored concomitantly with the time
dependence for leakage of intracellular lactate dehydrogenase
(LDH) as follows: after incubation with the peptide, 50 ml of the
supernatants was collected and transferred to new 96-well plates.
LDH-solution was added for 30 min. After stopping the reaction
the LDH release was measured at 490 nm by an Elx808 Ultra
Microplate Reader (Bio-Tek Instruments GmbH, Bad Friedrich-
shall, Germany). The remaining medium was immediately
replaced with fresh medium and cytotoxicity was determined by
MTT assay (see Cell vitality).
Localization analysis
Cells(35.000cells/chamber)wereseededandgrownfor24 hours
on chamber slides (Nalge Nunc International, Naperville, IL, USA).
After incubation with [D]-K3H3L9 at different time points (30 min,
4 h and24 h)cellswere fixedandtreatedwithcitrate bufferforhigh
temperature antigen retrieval. Blocking buffer was used to avoid
non specific binding. Rabbit-anti-[D]-K3H3L9 antibody (Polypep-
tide Laboratories, Strasbourg, France) was applied to detect the
position of the peptide within the cells. After incubation with a
biotinylated anti-rabbit antibody and Streptavidin Alexa Fluor 488,
nuclei were counterstained with DAPI (Invitrogen Corporation,
Carlsbad, CA, USA). Results were evaluated microscopically by a
Zeiss LSM-510 Meta confocal laser scanning microscope system
(Carl Zeiss Jena GmbH, Jena, Germany).
Membrane visualization
Cells (10.000 cells/cover glass) were seeded on sterile cover
glasses (12 mm in diameter, NeoLab, Heidelberg, Germany). After
24 h cells were incubated with a lethal dose (LD100, here: 50 mM)
of the [D]-K3H3L9 peptide or with PBS as a control for different
time points (30 min, 4 h, 24 h). Subsequently, cells were washed
with PBS and fixed in 3.7% glutardialdehyde, following
dehydration through an ascending alcohol series (50%, 70%,
90%, 100% EtOH, 5 min/step). After drying samples were coated
with gold particles and analyzed via a scanning electron
microscope (DSM 982, Carl Zeiss, Oberkochen, Germany).
Hemolytic activity
The hemolytic activity of the [D]-K3H3L9 peptide was
determined on human as well as murine erythrocytes. Therefore,
whole blood was removed and transferred into EDTA tubes. After
dilution of 5 ml blood in NaCl solution the suspension was
centrifuged by 1200 g without break for 5 min. The supernatant
(plasma) was discarded and erythrocyte suspension was washed with
NaCl until the supernatant was clear. A 2.8% (v/v) erythrocyte
suspension was prepared and incubated with different concentra-
tions of the peptide (0–100 mM) for different length of time (30 min,
2 h, 24 h). The absorbance of the supernatants was measured at
540 nm by an ELISA plate reader Elx808 Ultra Microplate Reader
(Bio-Tek Instruments GmbH, Bad Friedrichshall, Germany).
Correlating the measured values of treated (Asample) and untreated
(Acontrol) erythrocytes led to the percentage of hemolytic activity.
Total hemolysis (Atotal) was obtained by treating erythrocytes with
0.1% Triton-X100 (Merck, Darmstadt, Germany).
Hemolytic activity in %: Asample{Acontrol
 
Atotal{Acontrol ðÞ

|100
Solid tumor model
Human synovial sarcoma SW982 and murine fibrosarcoma
BSF-1 cells in Matrigel (BD Biosciences, San Jose, CA, USA) were
injected subcutaneously (1610
6 cells) into the animal’s flank. Every
second day mice were weighed and tumor volume was determined
with the formula of length6width6depth60.5 in mm
3. When the
tumor volume reached an averaged volume of 138 mm
3 (SW982)
and 130 mm
3 (BFS-1) the animals were grouped according to the
principles of a randomized control trial. [D]-K3H3L9 was injected
intratumorally three times per week for three weeks (single dose
8.5 mg/kg, SW982 n=7, BFS-1 n=6). Injection sites varied. PBS
(pH 7.0–7.5) was applied as control substance (SW982 n=5, BFS-
1 n=4). Animals were sacrificed and tumors were analyzed.
To verify the success of therapy a long-term experiment was
carried out. Mice were treated with the [D]-K3H3L9 peptide
(n=10) or PBS as a control (n=5) as described above. An
observation of tumor size followed over a period of six weeks. After
reaching a tumor length of over 20 mm the experiment was
terminated and the animals were euthanized. The evaluation of
the data was based on a Kaplan-Meier graph.
Histologic and immunofluorescent staining
Excised tumors were fixed in 5% buffered formaldehyde.
Paraffin-embedded 2–3 mm sections were stained with haematox-
ylin and eosin (H&E). Slides of tumors treated with [D]-K3H3L9 or
withPBSwere examined under a microscope(ZeissAxioskop 2 Plus
microscope) and photographed (AxioCam HRc). For immunohis-
tological examination slides were deparaffinized and rehydrated.
High temperature antigen retrieval in citrate buffer (Vector
Laboratories, Burlingame, CA, USA) was performed followed by
incubation with blocking buffers to avoid nonspecific binding of
antibodies. Tissue sections were incubated with monoclonal anti-
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many) specific to proliferating cells, anti-Laminin antibody (Sigma-
Aldrich, St. Louis, MO, USA) specific to the basal lamina as can be
found in blood vessels and anti-CD3 antibody (Acris Antibodies
GmbH, Herford, Germany) specific to T-cells. After incubation
with a biotinylated secondary anti rabbit antibody, Streptavidin
Alexa Fluor 488 conjugate was added. Nuclei were counterstained
with the fluorescence DNA dye DAPI. Results were evaluated
microscopically via a Zeiss Axioskop 2 Plus microscope. Pictures
were taken using an AxioCam HRc and the software Zeiss Axio
Vision 3.1. For quantitative analysis Ki67-positive cells were
counted. Therefore 10 high power fields (HPFs) (magnification:
4006) of non-necrotic areas of four different tumors from each
group were assessed by three independent investigators.
Results
In vitro activity of [D]-K3H3L9 at acidic and physiological
pH
The viability of the cells after treatment with [D]-K3H3L9 was
determined at physiological (pH 7.3) and acidic (pH 6.0)
conditions with the MTT assay. A disordered metabolic and
nutritional situation and an insufficient vascularisation often result
in an acidic extracellular environment in malignant tumor tissue.
Fig. 1 (a+b) shows the metabolic activity of the cells after
incubation with different concentrations of the peptide. In
physiological conditions (a) [D]-K3H3L9 shows a tendency for
selective activity against malignant cells compared to normal
primary fibroblasts. Note that the metabolic activity was
significantly (p,0.05) lower in an acidic milieu (b) compared to
physiological conditions in all tested cell lines, also in primary
fibroblasts. A comparison between primary human fibroblasts in
physiological pH, where they normally occur, and tumor cells in
acidic milieu, demonstrates the selectivity of [D]-K3H3L9 against
malignant cells. The LD50 of the tested sarcoma cells in acidic
milieu is 7.4 fold and 5.2 fold lower than that of the fibroblasts in
physiological condition for SW982 and BFS-1 cells, respectively.
Decrease of cell proliferation
The proliferation of the cells was measured by BrdU
incorporation into DNA (Fig. 1 (c)). Note that fibroblasts and also
the murine fibrosarcoma cell line BFS-1 show an increase of
Figure 1. Impact of cell metabolism and proliferation of human synovial sarcoma (SW982) and murine (BFS-1) cell line after
incubation with increasing concentrations of [D]-K3H3L9. (a) Metabolic activity of the cells in physiological conditions (pH 7.3). (b) Metabolic
activity of the cells in an acidic milieu (pH 6.3). The MTT-assay revealed dose-dependendent cytotoxic activity in both cases. The cell vitality was
significantly (p,0.05) lower in an acidic milieu compared to physiological conditions. (c) [D]-K3H3L9 displayed an anti-proliferative effect towards both
sarcoma cell lines. (d) Lethal dose (LD50 in mM) of human synovial sarcoma (SW982) and murine fibrosarcoma (BFS-1) cell line after incubation with
[D]-K3H3L9.
doi:10.1371/journal.pone.0018321.g001
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peptide. At higher dosage [D]-K3H3L9 displayed an antiprolifer-
ative effect towards both sarcoma cell lines. Noteworthy is the fact
that primary human fibroblasts need a 2 fold higher dosage for
reaching their LD50 value of 42.7 mM (Fig. 1(d)).
DNA-fragmentation after [D]-K3H3L9 treatment
The TUNEL assay allows the analysis of potential DNA-
cleavage, one of the results of apoptosis. Fig. 2 shows both tested
cell lines after incubation with different concentrations of the
peptide. As well as for the determination of cell vitality and
proliferation the assay revealed a dose dependence regarding the
genotoxic effect of [D]-K3H3L9. At a concentration of 25 mM the
synovial sarcoma cells (SW982) began to show DNA-fragmenta-
tion, whereas the fibrosarcoma cells (BFS-1) already showed an
effect at 12.5 mM. At a peptide concentration of 50 mM almost all
sarcoma cells could show DNA-cleavage. Note that the BFS-1 cells
show a destroyed structure after treatment with 50 mM of [D]-
K3H3L9 whereas SW982 cells have almost intact cell compart-
ments and membranes.
Time dependent membrane disruption
The parallel testing of cell vitality with MTT and membrane
disruption with the LDH assay at different time points can give a
hint of the mode of action of [D]-K3H3L9. Sarcoma cells were
treated with the previously determined LD50 of the peptide in 1, 2
and 4 multiples. Fig. 3 shows the viability of the sarcoma cell lines
(A) compared to the LDH release (B).
At a concentration of simple LD50 the synovial sarcoma cell line
SW982 did not show any limitation in cell vitality. The cells also
showed only a slight increase of the LDH release. Even after
24 hour incubation the release only increases to a value of
29.5 mM. The BFS-1 cells revealed a low decrease of vitality and
increase of LDH. Only after one day of incubation nearly all cells
have lost their membrane integrity. Note that still half of the BFS-1
cells are alive after 24 h. The membrane integrity of the cells after
incubation with [D]-K3H3L9 at the LD50 in 2 multiples showed a
parabolic curve progression with over hundred percent LDH
release after 24 h. The metabolic activity of the cells decreased
more slowly. After 4 h incubation only half of the cells (SW982:
50.9%, BFS-1: 53.2%) showed an inhibition of the metabolic
activity. After 24 h incubation the metabolism of the cells was
completely inhibited. Incubation of the cells with LD50 in 4
multiples showed comparable results. A strong decrease of cell
vitality even after low incubation periods is linked to a strong and
fast increase of LDH release. Nevertheless, the LDH release
appears to rise faster than the vitality decreases. These results
indicate that the destruction of membrane integrity causes the
decreased cell vitality after treatment with the peptide.
Cellular localization of [D]-K3H3L9
To investigate potential targets of [D]-K3H3L9 cells were
treated with a specific antibody against the HDP. Fig. 4 gives a
representative example of SW982 cells after incubation with [D]-
K3H3L9 at different time points. After 30 min the fluorescent
staining indicates a location of the peptide in membrane and
even in intracellular components. Note that the cells are in
structure, cell extensions are still visible. After 4 hours the cell
membrane is disrupted and most cell extensions are withdrawn.
The cells changed their morphological shape into a more
condensed form. The peptide is still located intracellular, the
nuclei are not involved. After 24 hours of incubation the peptide
also infiltrates the nuclei and cell membranes are often
completely destroyed.
Figure 2. DNA-fragmentation (TUNEL assay) after treatment with different concentrations (12,5 mM, 25 mM, 50 mM) of the peptide
and PBS as a control. An apoptotic effect of [D]-K3H3L9 could already be detected at a peptide concentration of 25 mM and 12.5 mM in SW982 and
BFS-1 cells, respectively. In the positive control the cells underwent DNA-cleavage after incubation with DNase I and were therefore labeled with
dUTPs (green). Negative controls received no treatment with the labeling enzyme TdT.
doi:10.1371/journal.pone.0018321.g002
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K3H3L9-NH2
The scanning electron microscopy images give a hint on the
mode of action of [D]- K3H3L9 on plasma cell membranes.
Fig. 5 visualizes the differences between control cells and cells
treated with [D]- K3H3L9 at indicated time points. Cells
treated with PBS are characterized by a smooth cell surface,
whereas even after a short incubation time of 30 min the cell
membrane is affected significantly which is demonstrated by a
starting loss of membrane integrity illustrated by thread-like
Figure 3. Parallel testing of (a) cell vitality with MTT- and (b) membrane disruption with the LDH-assay at different time points
(2 min, 15 min, 30 min, 2 h, 4 h, 24 h) and concentrations (LD50:1 6,2 6,4 6) of [D]-K3H3L9. The membrane integrity of the cells after
incubation with [D]-K3H3L9 at the LD50 in 2 and 4 multiples showed a parabolic curve progression with over hundred percent LDH release after 24 h.
The LDH release appears to rise faster than the cell viability decreases. These results indicate that the destruction of membrane integrity causes the
decreased cell vitality after treatment with the peptide.
doi:10.1371/journal.pone.0018321.g003
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destroyed.
Hemolytic activity of [D]-K3H3L9
The influence of the peptide against human and murine
erythrocytes was measured using the hemolysis assay. Fig. 6 shows
the hemolytic activity on human (a) and murine (b) erythrocytes
after incubation with different concentrations of [D]-K3H3L9.
After incubation times of 30 min and 2 hours both types of
erythrocytes show less than 10% hemolysis compared to the
positive control, even at highest peptide concentration. A 24 h
incubation period with the peptide could show an increase of
hemolytic activity in human erythrocytes up to 39%. Murine
erythrocytes could not be evaluated after 24 h as the control has
already had a strong hemolytic activity.
Inhibition of solid soft tissue sarcoma growth by
intratumoral administration of [D]-K3H3L9
Cellswereimplantedsubcutaneouslyinto the leftflankofathymic
nude (SW982) or immunocompetent C57BL/6 (BFS-1) mice. After
reaching the defined tumor volume the oncolytic activity of [D]-
K3H3L9 was assessed. The peptide was injected intratumorally at a
dose of 8.5 mg/kg. A significant inhibition of the tumor volume
could be reached after therapy in both models. As shown in
Fig. 7(a+b;d+e), the control groups of both, athymic and
immunocompetent mouse model, displayed exponential tumor
growth throughout the three-week therapy. The tumor volume
increasedtoa finalmeantumorvolumeof886 mm
3 and1979 mm
3
for SW982 and BFS-1 cells, respectively. The local administration
of [D]-K3H3L9 leads to a partial remission and in two cases to an
almost full remission of the tumor. Already after the third (SW982)
and fifth (BFS-1) injection, a significant (p,0.05) difference in
tumor growth was observed in both models. The mean tumor
volume at the end of the therapy reached a value of 290 mm
3 and
667 mm
3 for SW982 and BFS-1 tumors, respectively.
These findings were accompanied by a significant reduction
(p,0.05) in dissected tumor weight of the treatment group
compared to the control group (Fig. 7 (c)) on the last day of the
experiment for SW982 cells. The BFS-1 mouse model demon-
strated a tendency (p,0.09) for tumor weight reduction after
treatment with the peptide (Fig. 7 (f)).
The long-term experiment could give an indication of the
beneficial effect of the peptide for the period after therapy. We
observed the tumor growth up to six weeks after first injection of
the peptide. The Kaplan-Meier graph (Fig. 8) illustrates the
significant difference between the [D]-K3H3L9 treated animals
and the control mice. Whereas 100% of the PBS treated animals
had to be euthanized at the latest after 17 days due to excessive
tumor growth, 70% of the peptide treated mice survived the entire
period. Animals with complete remission of the tumor (2/10 mice)
did not show any tumor growth even after the six week-follow-up
(data not shown).
Histological examination of the tumor was done after resection.
Fig. 9 (a) presents two histopathological images (H&E) of
representative tumor sections of the synovial sarcoma cell line
SW982. In the control xenografts, the tumor contains large
numbers of dense, highly proliferative cancer cells. The decrease
in tumor staining, a poor nuclear-to-cytoplasmic ratio, and the loose
structure in the [D]-K3H3L9 treated mice indicates a massive tumor
cell death. This was further verified with Ki67 immunohistochem-
istry stainings. Fig. 9 (b) shows the results of the HPF-counting of
both cell lines. Control tumors had a significant (p,0.05) larger
amount of stained cells compared to therapy-treated tumors.
A strong antiangiogenic effect of the peptide could be determined
using an anti-laminin-staining. Fig. 9 (c) reflects the HPF-counting
of blood vessels after immunhistochemical staining with anti-
laminin antibody. In both cases (SW982 and BFS-1) a significant
inhibition of vessel formation are seen after [D]-K3H3L9 therapy.
A possible immunomodulatory effect of the peptide was
investigated based on an anti-CD3 staining (Fig. 9 (d)).Compared
to the athymic mice model the syngeneic BFS-1 model shows a
significant increase of T-cells in the tumor environment.
Investigating peptide-treated with carrier control-treated tumors
in the immunocompetent model could show a significant increase
of T-cells migration after [D]-K3H3L9 therapy (Fig. 9 (e)).
Discussion
The most important result is that [D]-K3H3L9 markedly
reduced tumor volume in both athymic and immunocompetent
Figure 4. Mode of action analysis with primary antibody
against [D]-K3H3L9. Representative images of SW982 cells treated
with a lethal dose of the peptide. After 30 minutes the peptide is
located in the cytoplasm. The cells still have a healthy structure and cell
extensions. After 4 hours of incubation the membranes are destroyed
and cell extensions are lost. 24 hour incubation with [D]-K3H3L9 leads to
a complete vanish of cytoplasm.
doi:10.1371/journal.pone.0018321.g004
Figure 5. Representative scanning electron microscopy images
of SW982 cells treated with [D]-K3H3L9 for 30 min and 24 h.
Magnification 2.0006(left column) and 10.0006(right column). Squares
represent further magnified region. The figures display a complete
membrane disruption after 24 hours.
doi:10.1371/journal.pone.0018321.g005
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mice. The histological evaluation showed necrotic debris in the
sections taken from the remaining tumors treated with [D]-
K3H3L9, and the density of the cells was very low (Fig. 7b). This is
in contrast with the significantly higher amount of mitotic cells in
the control tumors. These results demonstrate that the remaining
tumor does not proliferate normally. In addition, [D]-K3H3L9 is
selective towards and much more active on the sarcoma cells than
the primary human fibroblasts.
In STS treatment, designer HDPs may offer an alternative to
the low therapeutic indices and toxic side effects of chemother-
apeutic agents [11,27,28]. The [D]-K3H3L9 used in this study has
previously shown dramatic reductions of tumor growth in various
human prostate carcinoma xenografts [23]. Solid tumors often
Figure 6. Hemolytic activity of isolated (a) human and (b) murine erythrocytes after incubation with different concentrations (0–
100 mM) of the host defense-like lytic peptide [D]-K3H3L9. Even at highest concentration (100 mM) both types of erythrocytes show less than
10% hemolysis after 30 min and 2 hours. After 24 h incubation period human erythrocytes show an increased hemolytic activity up to 39%.
doi:10.1371/journal.pone.0018321.g006
Figure 7. In vivo studies. (a) Athymic nude mice model with human synovial sarcoma (SW982) tumor after treatment with PBS (control) and [D]-
K3H3L9. (b) After the third day of therapy a significant (* p,0.05) difference in tumor volume of control and peptide treated tumors could be
determined (c) Weight of SW982 tumors after three-week treatment with control substance and [D]-K3H3L9. Peptide treated tumors have a
significantly (p,0.05) diminished tumor weight (d) Syngeneic, immunocompetent mouse model with murine fibrosarcoma (BFS-1) tumor after
treatment with PBS (control) and [D]-K3H3L9 (e) After the fourth day of therapy the tumor volume of peptide treated mice was significantly (p,0.05)
diminished compared to control mice (f) Weight of BFS-1 tumors after treatment with control substance and [D]-K3H3L9.
doi:10.1371/journal.pone.0018321.g007
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to normal cells [20]. Fast tumor growth leads to an insufficient
vascularisation followed by a diminished wash out of acidic
products. In addition, the lack of oxygen contributes to an acidic
milieu [21]. The peptide [D]-K3H3L9 consists of lysines, histidines
and leucins. Histidine is protonated below pH 7, therefore the
peptide should be more cationic at low pH levels. The viability
testing in this study revealed an increasing activity of the peptide in
acidic environment compared to physiological conditions. A
comparison of cell viability between primary human fibroblasts,
which normally occur in physiological conditions, at pH 7.3, and
malignant cells in acidic milieu (pH 6.3) demonstrates a strong
selectivity of [D]-K3H3L9 against cancer cells. The proliferating
activity of fibroblasts and also murine fibrosarcoma cells first
increased after treatment with low concentrations of the peptide.
This could be due to an increased cell metabolism and additional
energy expenditure to transfer molecules across the cell membrane
in the extracellular matrix.
Because most chemotherapeutics act by damaging DNA or by
interfering with DNA replication, they need to enter the cell to be
functional [29]. Many malignant cells overexpress so called
multidrug resistant transmembrane proteins which are able to
remove the drug from the cell using ATP-dependent active
Figure 8. Survival rate of mice after long-term trial. The Kaplan-
Meier graph illustrates the differences in overall survival of mice after
treatment with [D]-K3H3L9 or PBS as a carrier control. Whereas 100% of
the carrier control animals had to be euthanasized before the expire of
the 6 weeks-follow-up, 70% of the peptide treated animals survived th e
entire period.
doi:10.1371/journal.pone.0018321.g008
Figure 9. Histological and immunohistological analysis. (a) Exemplary images of H&E stained tumor sections of SW982 cells (2006
magnification). The poor nuclear-to cytoplasmic ratio and large spaces between the cells of [D]-K3H3L9 treated tumors indicates a massive cell death.
(b) Anti-Ki-67 staining. A significant (p,0.05) reduction of proliferating cells could be detected in [D]-K3H3L9 treated cells compared to the carrier
control in both mice models. (c) Anti-laminin staining. Blood vessel density was significantly (p,0.01) diminished in peptide treated tumors
compared to the control. (d) Anti-CD3 staining. Compared to the athymic mouse model (SW982) a significant increase (p,0.01) of CD-3 stained T-
cells could be determined in [D]-K3H3L9 treated tumors of immunocompetent BFS-1 tumors. (e) Anti-CD3 staining. A comparison between peptide-
treated and control-treated tumors in the immune competent BFS-1 model could show a significant increase (p,0.01) of T-cell migration in [D]-
K3H3L9 treated tumors.
doi:10.1371/journal.pone.0018321.g009
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therapeutic agents is a common clinical problem in the treatment
of soft tissue sarcomas. HDPs kill malignant cells due to a unique
mechanism involving membrane disruption. The fact that there is
a difference between membranes of malignant and non-malignant
cells makes it possible to develop peptides with selectivity against
cancer cells. Whereas normal mammalian cells possess zwitterionic
membranes [30], cancer cells have a more negatively charged
membrane due to 3–9% phosphatidylserine or glycosaminogly-
cans [31,32]. The membranolytic activity of [D]-K3H3L9 was
previously analyzed towards model membranes and prostate
cancer cells [23]. In this study we detected typical signs of
membrane disruption. The premature LDH release gives a hint of
disruption of the membrane integrity as a basic cause of the
decreased cell vitality. By labeling the peptide via a specific
primary antibody we could show a destroyed cell membrane after
4 hours of incubation with a lethal dose of [D]-K3H3L9. These
results were further verified by using scanning electron microsco-
py. The cationic peptide may bind to the anionic structures (e.g.
phosphatidylserine) of the malignant cell membrane in a carpet-
like manner. After reaching a threshold concentration the peptide
may penetrate the membrane leading to a depolarization and
death of the cell [11]. Another reason for this selective membrane
disruption is the relatively high number of microvilli projections on
tumor cells. This leads to a larger surface and to the possibility of
higher levels of HDP interaction. Due to the strong membrano-
lytic activity of [D]-K3H3L9 tumor cells are probably not capable
to develop resistance. In previous studies bacteria treated with
cationic HDPs did not show any resistance against the adminis-
tered peptides [15,33].
In vivo, two xenograft models were used. Human synovial
sarcoma cells were injected into athymic, immune deficient nude
mice. Relatively few studies on oncolytic activity of HDPs have
been performed in syngeneic models. Immunocompetent mouse
models possess the advantage of investigating possible immuno-
modulatory properties of the peptides. Here the immunocompe-
tent C57BL/6 mice model was treated with syngeneic murine
fibrosarcoma cells (BFS-1). BFS-1 cells, originally induced in a
female C57BL/6 mouse after treatment with methylcholanthrene,
are now able to produce a tumor in an immunocompetent mouse
model. Due to its intact immune system this model is closer related
to clinical situations. Furthermore the model allows investigating
the potential involvement of HDPs in the innate and adaptive
immune system.
Here [D]-K3H3L9 could show significant oncolytic activity in
both sarcoma xenograft models. Tumors treated with the carrier
control PBS show an exponential growth, whereas tumors treated
with the [D]-K3H3L9 show partial or in two cases also total
remission of the tumor. An antiproliferating activity could be
demonstrated in histological and immunohistological samples after
treatment with the peptide.
In addition to the potent inhibition of tumor growth the
immunohistochemical laminin-staining of the tumors treated with
[D]-K3H3L9 revealed a significant decrease in vasculature
compared with untreated mice (Fig. 9 (c)). This may be the result
of either a reduced cancer cells density, yet unknown, direct
vascular targeting of the peptide or even a possible induction of
angiogenic inhibiting factors [34]. Soft tissue sarcoma are often
markedly angiogenic and highly dependent on their vasculature
for primary tumor growth as well as the development of metastases
[35]. Until now several antiangiogenic therapies are under
evaluation in human STS clinical trials [36,37]. The convincingly,
significant antiangiogenic effect of the peptide [D]-K3H3L9 in this
study hold major promise for successful sarcoma therapy but needs
further investigation.
On evaluating all the data from killing curves, localization
studies, membrane disruption experiments and histopathological
studies conducted on living cells under identical experimental
conditions, the results suggest a necrotic process. Although a
necrotic rather than an apoptotic mechanism of killing is
suggested, the details by which [D]-K3H3L9 kills sarcoma cells is
still not fully understood. Among the thousands of HDPs isolated
thus far, only a few have been investigated for their mode of action
on malignant cells [22]. Most of these studies included many
biophysical techniques conducted mainly with model phospholip-
id-membranes [22].
In summary, this study shows that [D]-K3H3L9 can be
administered intratumorally, and it dramatically reduces the
tumor growth of various sarcoma xenografts. Furthermore, it
has an antiangiogenic effect and causes a T-cell attraction in the
syngeneic mouse model (Fig. 9 (d+e)), which leads to the
assumption of an immunomodulatory effect of the [D]-K3H3L9
peptide. Note also that although peptides can be weakly
immunogenic, several reports indicate that free, short HDPs do
not induce an antibody response when injected into mice. In
addition, the immunogenicity of short fragments containing D-
amino acids has been shown to be reduced markedly compared
with their all-L- or all-D-amino acid derivates [38,39]. The unique
properties of the diastereomer and its strong membranolytic effect
should make it difficult for the tumor cell to develop resistance.
Furthermore, designer D-amino acid peptides represent a novel
class of oncolytic agents that should be further explored for
therapeutic use.
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